Press & News

ViewReleaseInStandardHtml

Boule Diagnostics – Nomination Committee for the 2018 Annual General Meeting

The Annual General Meeting, (”AGM”), 2017 of Boule Diagnostics AB (publ), (”Boule”), decided that a Nomination Committee based on the ownership structure as per September 30, 2017, will be appointed to propose for the AGM of 2018 the following items:

a)     chairman of the AGM,

b)     members of the board of directors,

c)     chairman of the board,

d)     remuneration to the members of the board and remuneration for additional committee work for each board member,

e)     auditor in charge,

f)      remuneration to the auditor, and

g)     nomination process for the AGM of 2019

Boule’s largest shareholders at the above date were Svolder AB, AB Grenspecialisten and Thomas Eklund, who combined represent over 30 percent of share capital and votes. Said shareholder have in turn nominated Ulf Hedlundh (Svolder AB), Emil Hjalmarsson (AB Grenspecialisten) and Thomas Eklund. The Nomination Committee has subsequently constituted and elected Ulf Hedlundh as chairman of the committee, and the chairman of the board, Peter Ehrenheim, as adjunct member of the Nomination Committee.

Shareholders that wishes to contact the Nomination Committee are welcome to contact the committee’s chairman, Ulf Hedlundh, by phone +46 8-440 37 73, or by email ulf.hedlundh@svolder.se. To ensure that proposals will have enough time to be evaluated properly, proposals should be submitted at the latest by February 15, 2018.

For further information, please contact:
Fredrik Dalborg, CEO and Group President, Boule Diagnostics AB, phone +46 705-58 51 05

Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 705-46 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a rapidly growing global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com 

The information was submitted for publication, through the agency of the contact person set out above, at 15.30 CET on November 13, 2017.